1 Title

- 2 Full Title: Enhancing Genetic Association Power in Endometriosis through Unsupervised Clustering
- 3 of Clinical Subtypes Identified from Electronic Health Records
- 4 Short Title: The genetics of clinical endometriosis subtypes

5 Authors

- 6 Lindsay Guare¹, Leigh Ann Humphrey², Margaret Rush², Meredith Pollie², Yuan Luo³, Chunhua
- 7 Weng⁴, Wei-Qi Wei⁵, Leah Kottyan⁶, Gail Jarvik⁷, Noemie Elhadad⁴, Penn Medicine Biobank,
- 8 Regeneron Genetics Center, Krina Zondervan⁸, Stacey Missmer⁹, Marijana Vujkovic¹⁰, Digna Velez-
- 9 Edwards⁵, Suneeta Senapati², Shefali Setia-Verma^{11*}
- 10 *Corresponding Author: Shefali Setia-Verma (shefali.setiaverma@pennmedicine.upenn.edu)

11 Affiliations

- 12 1. Genomics and Computational Biology, University of Pennsylvania
- 13 2. Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania
- 14 3. Northwestern University
- 15 4. Columbia University
- 16 5. Vanderbilt University Medical Center
- 17 6. Cincinnati Children's Hospital Medical Center
- 18 7. University of Washington
- 19 8. University of Oxford
- 20 9. Michigan State University
- 21 10. University of Pennsylvania
- 22 11. Department of Pathology and Laboratory Medicine, University of Pennsylvania

23 Abstract

Background: Endometriosis affects 10% of reproductive-age women, and yet, it goes undiagnosed
for 3.6 years on average after symptoms onset. Despite large GWAS meta-analyses (N > 750,000),
only a few dozen causal loci have been identified. We hypothesized that the challenges in
identifying causal genes for endometriosis stem from heterogeneity across clinical and biological
factors underlying endometriosis diagnosis.

29 **Methods:** We extracted known endometriosis risk factors, symptoms, and concomitant conditions 30 from the Penn Medicine Biobank (PMBB) and performed unsupervised spectral clustering on 4,078 31 women with endometriosis. The 5 clusters were characterized by utilizing additional electronic 32 health record (EHR) variables, such as endometriosis-related comorbidities and confirmed surgical 33 phenotypes. From four EHR-linked genetic datasets, PMBB, eMERGE, AOU, and UKBB, we extracted 34 lead variants and tag variants 39 known endometriosis loci for association testing. We metaanalyzed ancestry-stratified case/control tests for each locus and cluster in addition to a positive 35 36 control (Total $N_{endometriosis cases} = 10,108$).

37 **Results:** We have designated the five subtype clusters as pain comorbidities, uterine disorders, 38 pregnancy complications, cardiometabolic comorbidities, and EHR-asymptomatic based on 39 enriched features from each group. One locus, RNLS, surpassed the genome-wide significant 40 threshold in the positive control. Thirteen more loci reached a Bonferroni threshold of 1.3×10^{-3} 41 (0.05 / 39) in the positive control. The cluster-stratified tests yielded more significant associations 42 than the positive control for anywhere from 5 to 15 loci depending on the cluster. Bonferroni 43 significant loci were identified for four out of five clusters, including WNT4 and GREB1 for the 44 uterine disorders cluster, RNLS for the cardiometabolic cluster, FSHB for the pregnancy complications cluster, and SYNE1 and CDKN2B-AS1 for the EHR-asymptomatic cluster. This study 45 enhances our understanding of the clinical presentation patterns of endometriosis subtypes, 46 47 showcasing the innovative approach employed to investigate this complex disease.

Abbreviations 48

49	AOU	All of Us Biobank
50	eMERGE	electronic medical record and genomics network
51	EHR	electronic health record
52	GWAS	genome-wide association study
53	ICD	international classification of diseases
54	PMBB	Penn Medicine biobank
55	UKBB	United Kingdom biobank

Introduction 56

57 Endometriosis, a complex gynecological condition affects 10% of women of reproductive age globally and more than 50% of women with infertility (1), yet it often goes either undiagnosed 58 59 or misdiagnosed, leading to delayed diagnoses and delivery of effective therapy (2,3). 60 Endometriosis is primarily characterized by the presence of endometrial-like tissue outside of the uterus. For managing the condition without surgery, the main treatments include pain relief and 61 62 hormone-based therapies, neither of which are curative. A notable number of women with 63 endometriosis receive opioids for pain management, despite the need for more sustainable and 64 effective treatment options (4,5). On the other hand, hormonal therapies may have limitations to 65 utilization due to severe side effects or a desire to become pregnant. Typically, the treatment for 66 endometriosis often includes both medical and surgical approaches, however 30-50% of patients with severe endometriosis may require a second surgery within 3-5 years (6). The most 67 comprehensive surgical management involves a hysterectomy with bilateral salpingoophorectomy 68 69 (7). Treatment and health care visits accumulate many direct and indirect costs for women with 70 endometriosis. The estimated economic cost of endometriosis in the US is ~\$10k per patient which 71 is $\sim 14\%$ higher than that of diabetes (8), and does not include the costs patients incur by having to

miss work days because of their symptoms. In total, endometriosis presents a high economic burden that exceeds \$22 billion in the U.S. alone (9). The condition not only imposes significant costs but also involves severe symptoms, delayed diagnosis, limited treatment options, and financial strain: challenges that could be significantly mitigated with a more detailed understanding of the disease.

77 Electronic Health Records (EHRs) represent a rich, yet underutilized, data source for capturing the phenotypic spectrum of endometriosis (10). Although the symptoms for 78 79 endometriosis can be quite severe, including chronic debilitating pain, dyspareunia, and infertility, 80 the average time to diagnosis is 4.5 years (11), in part because the only way to definitively diagnose endometriosis is by surgical observation of endometrial lesions growing outside of the uterus (e.g. 81 82 abdominal cavity, pelvis, ovaries, etc.) (12). The variability in symptoms and disease presentation 83 adds to the difficulty of diagnosis and hinders the optimal use of electronic health records (EHRs) in 84 research for accurately identifying affected individuals and control subjects (13-15), which is 85 critical for understanding the disease and advancing treatment strategies. The depth and breadth of 86 EHR data provide a unique opportunity to apply unsupervised learning techniques for the 87 identification of distinct phenotypic clusters that may correspond to clinical subtypes of 88 endometriosis. Such an approach aligns with precision medicine's goal to tailor diagnosis and 89 treatment strategies to individual patient characteristics, potentially revealing novel insights into 90 the disease's pathophysiology.

91 Better understanding of the disease mechanisms of endometriosis could lead to improved 92 diagnostic practices, reducing costs to the healthcare system and improving quality of life through 93 treatment and earlier diagnosis for patients. In spite of the prevalence and severity of 94 endometriosis, etiology of endometriosis is still poorly understood. The pursuit thus far of 95 biomarkers and drug targets based on genetic contributions of disease in patients with 96 endometriosis has mainly included genome-wide association studies to identify genetic variants

97 contributing to the disease (16.17). Twin studies have estimated the heritability of endometriosis to be 47.5% (18), and common variants are estimated to contributed 26% of phenotypic variance 98 99 (19), but the largest GWAS to-date (N > 750,000, 60,674 cases) has only explained 9% of the 100 phenotypic variance (17). Although these recent advances in genomic studies have promised 101 insights into the underlying genetic mechanisms of endometriosis, yet the heterogeneity of the 102 disease presentation has consistently complicated these efforts. Traditional genetic association 103 studies have struggled to untangle the intricate web of genotypic and phenotypic diversity within 104 endometriosis patients, leading to a critical need for innovative approaches to dissect the disease's 105 complexity.

106 We hypothesized that underlying clinical heterogeneity is obscuring the genetic 107 mechanisms and preventing large-scale genetic studies from explaining more of the heritability. 108 Endometriosis causes a wide range of symptoms and concomitant conditions, including severe 109 chronic pain, gastrointestinal inflammation, and infertility. Additionally, many symptoms of 110 endometriosis are shared between other gynecological diseases such as primary dysmenorrhea. 111 ovarian cysts, and pelvic inflammatory disease; making symptom-based diagnosis challenging 112 (20,21). Recent studies have highlighted the importance of complex disease subtyping in improving 113 our understanding of the genetic mechanisms underlying endometriosis. For example, a recent 114 study on polycystic ovary syndrome (PCOS) used unsupervised clustering to identify three 115 subtypes of PCOS based on lab and biometric values before conducting genome-wide association 116 study for each subtype (22). This approach allowed for a more nuanced understanding of the 117 genetic basis of PCOS and could be applied to endometriosis to identify subtypes with distinct 118 genetic mechanisms. Building on the premise that a more nuanced understanding of endometriosis 119 subtypes could unlock new genetic associations, our study leverages unsupervised, phenotypic 120 clustering analysis of EHR data to systematically identify and characterize clinical subtypes of 121 endometriosis. By dissecting the heterogeneity inherent in the disease, we aim to increase the

power of genetic association analyses, facilitating the identification of subtype-specific disease mechanisms. This approach not only promises to enhance our understanding of endometriosis genetics but also to refine diagnostic criteria and inform more targeted and effective treatment strategies.

126 In conclusion, the complex nature of endometriosis, with its diverse symptoms and 127 overlapping features with other gynecological diseases, presents challenges for understanding its 128 genetic mechanisms. In this manuscript, we detail the methodology and findings of our study, which 129 integrates unsupervised phenotypic clustering with subsequent genetic association analyses for 130 each identified endometriosis subtype. By doing so, we aim to bridge the gap between clinical observations and genetic research in endometriosis, providing a roadmap for future studies to 131 132 explore the genetic underpinnings of this complex disease with renewed clarity and precision. This 133 deeper understanding may pave the way for more targeted and personalized approaches to 134 diagnosis, treatment, and management of this debilitating condition. Further research and large-135 scale genetic studies are needed to fully elucidate the genetic architecture of endometriosis and its 136 subtypes, ultimately leading to improved outcomes for affected individuals.

137 Methods

138 Datasets Used for Sub-phenotyping and Genetic Association

The Penn Medicine Biobank (PMBB) is the University of Pennsylvania's health systembased biobank which consists of about 250,000 consented participants, with 43,624 of those having imputed genotype data (imputed to TOPMED reference panel) linked with their electronic health record (EHR) history. The PMBB is an electronic health record (EHR)-linked biobank that integrates a wide variety of health-related information, including diagnosis codes, laboratory measurements, imaging data, and lifestyle information, with genomic and biomarker data. The PMBB is one of the

most diverse medical biobanks, with approximately 30% of participants being of non-European ancestry. This diversity is crucial for ensuring that research findings are applicable to a broad range of populations. The biobank also benefits from a median of seven years of longitudinal data in the EHR, providing valuable information on participants' health histories (22). For our study, we treated the PMBB as two distinct datasets: those without and those with genotype data. EHR data from the non-genotyped PMBB were used for cluster derivation whereas the genotyped PMBB cohort was used in the genetic analyses.

152 The Electronic Medical Records and Genomics (eMERGE) network is a National Human 153 Genome Research Institute-funded consortium engaged in the development of methods and best 154 practices for using the electronic medical record as a tool for genomic research. The eMERGE network is a publicly-available dataset with contributions from multiple health systems within the 155 156 United States which contains about 100,000 participants with linked health records and imputed 157 genomic data (imputed to HRC reference panel) (23). The eMERGE consortium validated the 158 hypothesis that clinical data derived from electronic medical records can be used successfully for 159 complex genomic analysis of disease susceptibility across diverse patient populations (24). The 160 eMERGE network has shown the efficiency that can result from the use of electronic health record 161 data.

The All of Us (AOU) Research Program is an initiative created by the NIH to recruit demographically diverse individuals to the largest US-based biobank to-date. Recruitment began in 2018, and since then, over 400,000 people have signed up and submitted baseline questions (25). 245,388 of them have short-read whole genome sequence data, collectively representing over one billion genetic variants (26). Participants' EHRs are contributed to the AOU data processing center using the Sync for Science platform (27), which works with EHR vendors such as Epic and Cerner to collate structured patient data for research use (28).

The UK Biobank (UKBB) is a large and comprehensive dataset that provides valuable

170 resources for researchers studying a wide range of health-related topics. The UKBB is a population171 based publicly available dataset consisting of about 500,000 UK citizens with EHR data, health
172 survey data, and imputed genotypes. The UK Biobank has performed genome-wide genotyping on
173 all participants using the UK Biobank Axiom Array (29). This array directly measures
174 approximately 850,000 variants, and more than 90 million variants are imputed using the
175 Haplotype Reference Consortium and UK10K + 1000 Genomes reference panels.

169

176 All four of the biobanks mentioned above (PMBB, eMERGE, AOU, and UKBB) utilize the 177 Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) to represent 178 structured EHR data in a harmonized format (30). For this study, we utilized women with ICD-179 diagnosed endometriosis in the non-genotyped PMBB cohort ($N_{endo} = 4,078$) as the derivation 180 dataset for the clinical subtypes. For deeper characterization of our subtypes, we performed chart-181 reviews on 682 randomly selected endometriosis cases from the genotyped PMBB. Then, we meta-182 analyzed women from the genotyped PMBB (N = 20,697, N_{endo} = 1,198), six non-pediatric sites 183 within the eMERGE network (N = 51,800, N_{endo} = 2,243), the AOU research program (N = 108,098, 184 $N_{endo} = 2,126$), and UKBB (N = 261,824, $N_{endo} = 4,451$) to form our main genetic analysis test set (N = 185 $442,419, N_{endo} = 10,018$).

Each of the biobanks projected their samples onto the thousand genomes reference population and performed clustering to assign genetically inferred ancestry labels corresponding to those from the thousand genomes project (31). We restricted our genetic association analyses to the groups which had substantial sample sizes, which were those with high similarity the AFR and EUR thousand genomes superpopulations. We will refer to those groups using AFR and EUR from here on out.

192 Extraction of Endometriosis-Related Clinical Features

193 Patients with endometriosis have heterogeneous clinical presentations; there are a wide 194 variety of associated symptoms, risk factors, and comorbidities. We first determined participants' 195 case-control status of endometriosis using structured EHR data: ICD-9 and ICD-10 billing codes 617 196 and N80, respectively. Then for endometriosis cases, we determined whether each individual had a 197 history of endometriosis-related clinical features. In total, we extracted 39 ICD-based features 198 (Table S1): 9 ICD-based anatomical subtypes, 14 comorbidities, 8 symptoms, and 8 pregnancy-199 related phenotypes. We selected only symptoms, comorbidities, and pregnancy-related conditions 200 for clustering, removing the 9 anatomical subtypes to be used downstream in cluster 201 characterization. We further restricted these conditions to those with a prevalence amongst 202 endometriosis cases in the subtype dataset of at least 5%, leaving us with 17 features for the 203 clustering analysis (Figure S1).

204 Unsupervised Clustering

205 We tested four popular methods for unsupervised clustering: spectral clustering, density-206 based spatial clustering of applications with noise (DBSCAN), hierarchical agglomerative clustering, 207 and k-means clustering. Spectral clustering identifies clusters by decomposing a dataset's affinity 208 matrix into its eigenvectors and then clustering in the eigenvector space using QR clustering 209 algorithm (32,33). DBSCAN is an algorithm which identifies dense regions of data points to discover 210 clusters (34). Hierarchical agglomerative clustering is an unsupervised classification method that 211 uses a pairwise distance matrix to iteratively merge nearby points together (35). K-means 212 clustering randomly initializes centroids for each cluster and then alternates between assigning 213 data points to their nearest centroid and adjusting the centroids until convergence (36).

In addition to choosing an algorithm, a common struggle with unsupervised clustering is
choosing a target number of clusters in a non-arbitrary way. We used several empirical metrics for

216 this: silhouette score, distortion score, and a metric we developed to represent the "evenness" of 217 clusters. The silhouette score is a metric which considers both intra- and inter-cluster distances to 218 assess tightness within a cluster and distance between clusters; higher silhouette scores indicate 219 better quality clusters. The distortion score is the sum of squared errors with respect to the 220 centroid of each cluster, thus it is desired to minimize distortion. Our evenness metric, optimized by 221 minimization, was defined as the fractional difference between the size of the largest and smallest 222 clusters. We measured these metrics across tests for 2-20 clusters for each of the four clustering 223 methods (except for DBSCAN which automatically infers the optimal number of clusters).

224 Characterization of Unsupervised Clusters

225 After identifying clinical clusters within our observation dataset, our objective was to 226 delineate their characteristics. We performed two-population z-score proportion tests (37) to 227 determine if the rates of input conditions were significantly different on a cluster-vs-other-clusters 228 basis. For our training set (the non-genotyped PMBB, $N_{endo} = 4,078$), we examined two sets of 229 features for the z-score tests: the 17 input features as well as ICD-based anatomical subtypes of 230 endometriosis including adenomyosis, endometrioma, superficial lesions, and deep lesions 231 (Supplementary Table S2). For characterizing our clusters, we also utilized a chart-reviewed 232 dataset of 682 genotyped PMBB patients with endometriosis ICD codes. The features considered 233 here were confirmed endometriosis and adenomyosis status and chart-abstracted symptoms, 234 comorbidities, and surgical phenotypes (Supplementary Table S3). By considering the clusterspecific differences in these EHR-derived features among the two datasets, we could observe 235 236 patterns in clinical presentation. Based on these patterns, we assigned labels to each cluster.

237 Cluster-Stratified Candidate Gene Association Testing

To identify genetic heterogeneity among the varied clinical presentations of endometriosis,
we performed cluster-stratified, ancestry-stratified candidate gene association studies. Using PLINK

240 2.0 (38), we extracted single nucleotide polymorphisms (SNPs) in LD (kb distance < 0.5 Mb and R^2 > 241 0.1) with 39 autosomal lead SNPs reported in the most recent endometriosis GWAS(17). LD was 242 computed based on the thousand genomes reference panel (31). Cluster phenotypes were assigned 243 for PMBB, eMERGE, and AOU using a K-Nearest neighbors' classifier (39) with K=3 on the same 17 244 ICD-based features. For each study, we employed a linear mixed model regression method 245 employed in SAIGE (40) to test for associations between genotypes and case-control status. Cases 246 were females with endometriosis from one cluster and controls were biological females with no ICD 247 history of endometriosis. In the regression models we included the first four principal components, 248 age, and batch indicators (eMERGE only) as covariates. The ancestry-stratified results of these 249 studies were then meta-analyzed using Plink 1.9 (41) for each of the cluster-phenotypes. We also 250 tested a baseline overall endometriosis (cases from all clusters combined) as a positive control to 251 identify how many known loci we were able to replicate. Because multiple genetic ancestry groups 252 were included, we chose a random-effects meta-analysis, which is more robust to heterogeneity 253 (42)

254 Results

255 Derivation, Study, and Validation Datasets

This study utilized five datasets to investigate the genetic mechanisms underlying endometriosis and its subtypes. The datasets used were endometriosis cases in the non-genotyped PMBB for the derivation of clusters, a chart-reviewed endometriosis cohort to help characterize the clusters, the genotyped PMBB, six sites within the eMERGE network, AOU, and UKBB for genomewide association analyses (See Methods). The sample sizes for each cohort, the mean age at diagnosis, the number of cases and controls, and the mean age at the time of data pull for each cohort are shown in Table 1. See Methods for details on each of the four datasets. By leveraging

- these datasets, the study aimed to identify endometriosis subtypes and gain insights into the
- 264 genetic factors associated with endometriosis and its subtypes.

265

Table 1: Cohort sample size and average age of cases and controls for the datasets used in this

analysis. Age was considered the age as of when the EHR data were collected.

Dataset	Endometriosis	N (AFR / EUR)	Mean Age (SD)						
Cluster Derivation Set:									
Non-Genotyped PMBB	Cases	4,078 (NA)	49.9 (13.3)						
Genetic Association Sets:									
4011	Cases	2,126 (542 / 1,584)	52.2 (12.8)						
AOO	Controls	108,099 (31,435 / 76,664)	56.8 (16.8)						
AMEDCE	Cases	2,243 (353 / 1,890)	59.9 (14.6)						
emerge	Controls	49,557 (9,934 / 39,623)	59.7 (23.4)						
DMDD	Cases	1,198 (562 / 636)	54.2 (12.9)						
FMBB	Controls	19,493 (6,524 / 12,969)	60.0 (17.8)						
ШИДД	Cases	4,541 (112 / 4,429)	51.5 (7.5)						
UKDD	Controls	257,283 (4,524 / 252,759)	56.6 (8.0)						
Meta-Analysis Totals:									
МЕТА	Cases	10,108 (1,569 / 8,539)	53.9 (11.3)						
META	Controls	434,432 (52,417 / 382,015)	57.1 (13.6)						

269 Derivation of Unsupervised of Clusters

Unsupervised clustering was performed in non-genotyped PMBB dataset of 4,078 women with EHR-diagnosed endometriosis using 17 clinical features (supplementary figure S2). We tested four methods for unsupervised clustering as well as 19 values for the number of clusters (K=2-20) and measured three metrics to empirically choose a clustering method and number of clusters (Figure 1).



Figure 1: testing various clustering algorithms and K-values to empirically choose an optimal
method. The three metrics shown are (a) Manhattan-distance-based silhouette score, (b) distortion

²⁶⁸

or sum of squared errors, and (c) evenness represented by the difference in fraction between the
largest and smallest clusters. Based on these tests, we chose spectral clustering with K=5.

280

281 Based on these tests, we first eliminated DBSCAN because the inferred number of clusters 282 was 131, a far too complex model to be useful or interpretable. Next, we eliminated hierarchical 283 clustering because the sizes of the resulting clusters were more uneven than the other methods. 284 Spectral clustering and k-means clustering were ultimately more difficult to choose between, but 285 when we focused on the shapes of the distortion curves across the values of K, we observed that k-286 means lacked an "elbow" to show a clear optimal K value whereas spectral clustering clearly 287 indicated 5 as an ideal K with a local minimum. Thus, we chose spectral clustering with K=5 as our 288 unsupervised subtyping model. The sizes of the final clusters were: (1) 441 - 11%, (2) 686 - 17%, 289 (3) 1,151-28%, (4) 796 - 20%, and (5) 1,004 - 25%. Figure 2 illustrates the eigenvectors of the 290 affinity matrix which were used for clustering the data points.



Figure 2: pairwise scatter plots of the first five eigenvectors of the affinity matrix used for spectral
 clustering, colored by cluster. This five-dimensional eigenvector space was used for clustering. The
 diagonal shows kernel density estimator plots for each of the five eigenvectors.

296

295

297 Data-Driven Cluster Characterization

After clustering, we aimed to characterize these clusters by observing patterns in clinical presentation (prevalence) amongst the input features. We performed two sets of z-score proportion tests comparing prevalence of each feature between each cluster and the other four clusters in our training set. The first set of tests was performed on the original cluster derivation cohort, and the features included were the 17 input features (symptoms and comorbidities with prevalence > 5%) as well as ICD-defined anatomical subtypes of endometriosis (Figure 3).



304

Figure 3: feature tests for the non-genotyped PMBB training set. Shown are (a) z-scores for the
 difference in proportion tests, annotated with p-values that are significant and (b) feature
 prevalence by cluster to provide context for the z-score tests.

308

Among the five clusters identified in the training set, there were many input features and
 ICD-based anatomical subtypes with significantly different proportions. To identify distinguishing

311 features between the clusters, we focus on phenotypes which were significantly enriched and had 312 the highest prevalence in that cluster. Cluster one had the highest rates of (and was significantly 313 enriched for) dysuria (Z=8.9), migraine (Z=10.6), IBS (Z=10.3), fibromyalgia (Z=15.3), asthma 314 (10.3), abdominal pelvic pain (Z=13.6), and shortness of breath (Z=13.5). Cluster two had the 315 highest rates of the following significantly enriched traits: dysmenorrhea (Z=21.9), infertility 316 (Z=5.9), irregular menstruation (Z=31.75), leiomyoma of uterus (Z=21.9), and uterine 317 endometriosis defined by ICD-9 617.0* or ICD-10 N80.0* (Z=13.4). Cluster three's defining features 318 were high risk pregnancy supervision (Z=7.1), superficial lesions defined by ICD-9 617.3* or ICD-10 319 N80.3 * (Z=7.1), and lower abdominal pain (Z=14.6). Individuals in cluster four had highest 320 prevalence of abnormal cholesterol (Z=33.1) and hypertension (Z=33.9), while cluster five was only 321 enriched for unspecified endometriosis defined as ICD-9 617.9* or ICD-10 N80.9* (Z=7.0).

The second set of tests was performed on a subset of endometriosis cases (N=682) from the genotyped PMBB for whom chart reviews were performed by OB-GYN clinical fellows at the University of Pennsylvania Hospital System. The features tested were gold standard confirmed diagnoses (endometriosis, adenomyosis, fibroids, and any ICD false positives), surgical subtypes, hormone use at the time of confirmation procedure, and symptoms identified from a combination of structured data and notes (Figure 4).



328

329

330

331

Figure 4: feature tests for the chart reviewed PMBB dataset. Shown are (a) z-scores for the difference in proportion tests, annotated with p-values that are significant and (b) feature prevalence by cluster to provide context for the z-score tests.

Because the size of our chart-reviewed dataset was limited, there were fewer significant 332 333 tests. For cluster one, the phenotypes which were most significantly prevalent were interstitial cystitis (Z=3.8) and fibromyalgia (Z=6.9). For cluster two, the defining features were confirmed 334 335 adenomyosis status (Z=3.7), confirmed uterine fibroids (Z=7.1), and symptomatic bleeding (Z=5.3). 336 Cluster three's most highly enriched features were pelvic pain (Z=3.5) and hormone use at the time of surgery (Z=4.1). Considering the enriched features for each cluster among the two sets of tests, 337 338 we defined the following labels for 5 clusters: (1) pain comorbidities, (2) uterine disorders, (3) 339 pregnancy complications, (4) cardiometabolic comorbidities, and (5) EHR-asymptomatic.

340 Candidate Gene Association Testing Stratified by Phenotypic Cluster

341 We applied the subtype classifications observed in our derivation set to our four genetic

342 association datasets, PMBB, eMERGE, AOU, and UKBB. We used a K-nearest neighbors model with

343 the same 17 EHR-derived features to assign endometriosis cases to the five phenotypes (Table 2).

344

Table 2: counts and proportions of endometriosis cases in each cluster by dataset.

Dataset	Pain	Uterine	Pregnancy	Cardiometabolic	EHR-				
	Comorbidities	Disorders	Complications	Comorbidities	Asymptomatic				
Cluster Derivation Set:									
Training	441 (10.8%)	686 (16.8%)	1,151 (28.2%)	796 (19.5%)	1,004 (24.6%)				
Genetic Association Sets:									
AOU	713 (21.8%)	690 (21.1%)	723 (22.1%)	783 (23.9%)	362 (11.1%)				
eMERGE	495 (22.1%)	505 (22.5%)	382 (17.0%)	709 (31.6%)	152 (6.8%)				
PMBB	200 (16.7%)	222 (18.5%)	273 (22.8%)	366 (30.6%)	137 (11.4%)				
UKBB	231 (5.1%)	607 (13.4%)	842 (18.5%)	285 (6.3%)	2,576 (56.7%)				
Meta-Analysis Totals:									
META	1,639 (14.6%)	2,024 (18.0%)	2,220 (19.7%)	2,143 (19.0%)	3,227 (28.7%)				

345

346

The smallest cluster was the pain comorbidities cluster, with only 14.6% of total

347 endometriosis cases being assigned to this cluster. The EHR-asymptomatic cluster was the largest

348 cluster overall. The other three clusters occurred in relatively even proportions in the overall

meta-analysis group at 18.0% (uterine disorders), 19.7% (pregnancy complications), and 19.0%

350 (cardiometabolic comorbidities).

351 To establish a reference for the expected level of signal replication, we began with a positive

352 control test. We conducted association tests on 39 established genetic locations (autosomes only)

known to be linked to endometriosis. (Figure 5).





358

354

359 Our positive control test resulted in fourteen replicating loci. Only one was genome-wide 360 significant, RNLS/10q23.31 (P = 1.91x10⁻⁹, rs792212:T). Thirteen were significant at a Bon Ferroni-361 corrected threshold of 0.05 / 39: WNT4/1p36.12 (P = 9.12x10⁻⁸, rs2235529:T), DNM3/1q24.3 (P = 362 3.54x10⁻⁵, rs655853:C), *GREB1/2p25.1* (P = 6.55x10⁻⁴, rs34532804:A), *PDLIM5/4q22.3* (P = 8.58x10⁻⁵) 363 ⁴, rs1493112:T), *EBF1/5q33.3* (P = 7.64x10⁻⁴, rs1878936:C), *SYNE1/6q25.1* (P = $3.20x10^{-4}$, rs13206045:C), GDAP1/8q21.11 (P = 4.19x10⁻⁷, rs10957712:T), CDKN2B-AS1/9p21.3 (P = 1.75x10⁻⁶, 364 rs10122243:T), ASTN2/9q33.1 (P = 9.01x10⁻⁴, rs62576127:A), ABO/9q34.2 (P = 5.87x10⁻⁴, 365 366 rs495828:G), FSHB/11p14.1 (P = 1.17×10^{-3} , rs11031006:A), WT1/11p14.1 (P = 2.85×10^{-4} . 367 rs72638188:T), *DLEU1/13q14.2* (P = 2.24x10⁻⁴, rs9568417:G).

To test whether stratifying by clinical presentation allowed for greater resolution in genetic associations, we performed case-control candidate gene association studies for the five phenotypic clusters by meta-analyzing ancestry-stratified summary statistics from four EHR-linked genetic datasets: PMBB, eMERGE, AOU, and UKBB. We observe 18 / 39 loci (46%) significantly associating with one or more clusters (Figure 6a, 6b). Also, for up to 15 loci, the cluster-stratified phenotypes

373 yield stronger associations than the positive control despite having smaller sample sizes (Figure

374 6c).







The smallest cluster, cluster one, with high rates of pain comorbidities, was not significantly associated with any known loci, but it was more significantly associated than the positive control for eight loci as shown in Figure 6c. The uterine disorders cluster (two) was significantly associated with four loci, *WNT4/1p36.12*, *DNM3/1q24.3*, *GREB1/2p25.1*, and *GDAP1/8q21.11*. Out of the seven

385 loci significantly associated with the pregnancy complications cluster (three), three of them were not significantly associated with any other clusters or the positive control: *KDR*/4q12, 7p15.2, and 386 387 KCTD9/8p21.2. Cluster four, enriched for cardiometabolic comorbidities, was significantly 388 associated with one locus. RNLS/10q23.31, the strongest hit from the positive control, RNLS was 389 also significantly associated with clusters three and five. Eleven loci were significantly associated 390 with the EHR-asymptomatic cluster, and six of those (BSN/3p21.31, ID4/6p22.3, CD109/6q13, 391 MLLT10/10p12.31, IGF1/12q23.2, and SKAP1/17q21.32) had no other associations, even with the 392 positive control.

393 Discussion

394 Endometriosis presents with heterogeneous symptoms ranging from severe pain to 395 infertility, contributing to varying patient experiences and treatment responses. Several large 396 genome-wide association studies and meta-analyses have been performed for endometriosis to-397 date. However, the genomic underpinnings of endometriosis remain incompletely understood, 398 largely due to the clinical heterogeneity and the limitations of traditional genome-wide association 399 studies (GWAS) that aggregate all cases into a single analysis pool. This approach may obscure 400 genetic variations specific to different endometriosis phenotypes, thus necessitating more refined 401 stratification techniques. There are various approaches to phenotyping participants for these 402 studies including surgical notes and electronic health records. While there have also been analyses 403 which account for disease progression (17), there have not been any genome-wide investigations 404 into the genetics underlying the heterogeneous presentation patterns of endometriosis.

In this study, we aimed to investigate the genetics of heterogeneity in endometriosis by defining data-driven subtypes in women from the non-genotyped PMBB endometriosis population (N=4,078). We extracted clinical features known to be associated with endometriosis and performed unsupervised spectral clustering, identifying five clusters. Unsupervised clustering was

an ideal approach for this study because it a way to find patterns in the data without introducing
prior knowledge or bias. We chose spectral clustering with five clusters based on empirical metrics
measured by comparing four different unsupervised clustering methods across a range of K values
(2-20 clusters). This method had the best tradeoff between squared error, silhouette score, and
cluster evenness.

To understand the clinical presentation patterns of each of the clusters, we compared the rates of the input features, diagnoses, and chart-reviewed phenotypes amongst them. Based on statistical enrichment testing across the features, the clusters were labeled as (1) pain comorbidities, (2) uterine disorders, (3) pregnancy complications, (4) cardiometabolic comorbidities, and (5) EHR-asymptomatic. This nuanced phenotyping, which diverges from traditional classifications, allows for a deeper understanding of the pathophysiological variations within endometriosis and highlights the necessity of tailored therapeutic approaches.

421 After deriving and characterizing the clusters in the non-genotyped PMBB, we used a k-422 nearest neighbors' model to transfer the subtypes to the other four EHR-linked genetic datasets. 423 PMBB, eMERGE, AOU, and UKBB. We performed ancestry-stratified candidate gene testing for each 424 of the clusters using SAIGE and identified eight genome-wide significant signals. The genetic 425 analysis of these clusters yielded intriguing results. While 46% of previously known GWAS loci 426 were replicated in our study, significant differences in loci associations across the clusters were 427 observed. For instance, genes like WNT4 and GREB1 showed specific associations with the uterine 428 disorders and EHR asymptomatic clusters, suggesting that these genes might play distinct roles in 429 the pathogenesis of these phenotypic presentations of endometriosis. Conversely, the BSN gene, 430 although not statistically significant, demonstrated greater significance in the pain and pregnancy 431 complications clusters, indicating a possible link to neurovascular or inflammatory mechanisms 432 that could exacerbate these conditions.

433 Renalase (RNLS) is the protein associated with our only genome-wide significant 434 association from the positive control, RNLS/10q23.31. At the Bonferroni significance threshold, the 435 association with RNLS was significant for three out of five sub-phenotypes: pregnancy 436 complications, cardiometabolic comorbidities, and EHR-asymptomatic. It was the only significant 437 association with the cardiometabolic cluster. *RNLS* is highly expressed in the heart and contributes 438 to regulating blood pressure (43). In genetic association studies, *RNLS* has been previously 439 associated with type 1 diabetes (44) and smoking initiation (45). Smoking is a known risk factor of 440 endometriosis.

Cluster three, with high rates of pregnancy-related complications such as infertility and
high-risk pregnancy, was significantly associated with seven loci including *FSHB* (P = 1.8 x 10⁻⁴).
The *FSHB* gene codes for the beta-subunit of follicle-stimulating hormone (FSH). FSH is essential for
female fertility and has been shown to regulate myometrial contractile activity (46). *FSHB* was
significantly associated with the positive control as well, but not with any of the other clusters.

446 Cluster five, which was largely asymptomatic in the EHR, was the largest cluster. Over half 447 (56%) of UKBB endometriosis patients were assigned to this cluster. It is possible that those 448 assigned to this cluster from any dataset have symptoms that were not recorded in the structured 449 data which we had access to. Two well-known endometriosis loci from both of the last major 450 GWASs are SYNE1 and CDKN2B-AS1 (16,17), both of which were significantly associated with the 451 positive control and the EHR-asymptomatic cluster. Six loci were associated with this cluster and no 452 other phenotypes: BSN, ID4, CD109, MLLT10, IGF1, and SKAP1. MLLT10 and BSN have been 453 previously associated with pain perception and maintenance (17). Serum levels of IGF-1 are 454 significantly elevated in women with endometriosis (47). Gene expression of *ID4* is down-regulated 455 in eutopic and ectopic endometrial tissue of women with endometriosis (48). CD109I and SKAP1 have been previously associated with endometrial cancers (49,50). 456

458 Subtyping complex diseases, like endometriosis, is crucial for advancing precision medicine. 459 The findings from our study underscore the utility of EHR as a rich resource for disease subtyping 460 and genetic research. The linkage of detailed clinical data with genetic information enables the 461 identification of phenotype-genotype correlations that are often diluted in broader GWAS analyses. 462 Furthermore, the use of spectral clustering helps elucidate the heterogeneity within endometriosis, 463 providing a framework for understanding the multifaceted nature of the disease and facilitating the 464 development of personalized medicine.

465 However, it is essential to acknowledge the limitations of our study. One significant 466 constraint was the sample size, which was particularly limited for some of the smaller clusters and 467 for individuals of non-European ancestry. This limitation could potentially introduce bias and affect 468 the generalizability of our findings. Additionally, our study relies on structured electronic health 469 data only, which may not capture the full clinical picture and could be subject to inaccuracies or 470 incomplete records. Lastly, this genetic association analyses in this study only focused on the 471 candidate genes that are previously known to be associated with endometriosis. This approach 472 might have restricted our ability to discover novel genetic loci potentially relevant to the specific 473 clusters identified. Despite these limitations, our study marks a meaningful advancement in 474 understanding the genetic factors that may contribute to the heterogeneity observed in 475 endometriosis. By focusing on genetic associations gleaned from electronic health records, we offer 476 a novel perspective that could be instrumental in future research and treatment approaches. To 477 expand upon the current findings, future research should aim to perform comprehensive GWAS 478 across the identified endometriosis subtypes. This will enable the detection of novel loci that could 479 be crucial for understanding the distinct mechanisms underlying each subtype. Additionally, 480 integrating multi-omics data (such as transcriptomic, proteomic, and metabolomic data) could 481 further refine the molecular signatures associated with each cluster, enhancing the biological 482 interpretability of the genetic associations. Another promising avenue is the longitudinal study of

these clusters to assess disease progression and treatment outcomes, which could inform moreeffective, personalized therapeutic strategies.

In conclusion, our research highlights the importance of subtype-specific studies in elucidating the genetic basis of endometriosis. By leveraging the capabilities of EHR-linked biobanks and employing advanced clustering techniques, we pave the way for more targeted and effective approaches to understanding and managing this complex disease.

489 Acknowledgements

490 Research reported in this publication was supported by the Eunice Kennedy Shriver National
491 Institute of Child Health and Human Development of the National Institutes of Health under award
492 number R01HD110567.

493

We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patientparticipants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.

501

This phase of the eMERGE Network was initiated and funded by the NHGRI through the following grants: U01HG008657 (Group Health Cooperative/University of Washington); U01HG008685 (Brigham and Women's Hospital); U01HG008672 (Vanderbilt University Medical Center); U01HG008666 (Cincinnati Children's Hospital Medical Center); U01HG006379 (Mayo Clinic); U01HG008679 (Geisinger Clinic); U01HG008680 (Columbia University Health Sciences);

- 507 U01HG008684 (Children's Hospital of Philadelphia); U01HG008673 (Northwestern University);
- 508 U01HG008701 (Vanderbilt University Medical Center serving as the Coordinating Center);
- 509 U01HG008676 (Partners Healthcare/Broad Institute); and U01HG008664 (Baylor College of
- 510 Medicine).
- 511
- 512 We gratefully acknowledge All of Us participants for their contributions, without whom this
- research would not have been possible. We also thank the National Institutes of Health's All of Us
- 514 Research Program for making available the participant data examined in this study.
- 515
- 516 This research has been conducted using the UK Biobank Resource under Application Number
- 517 32133.

518 References

- Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL. Economic burden of endometriosis. Fertil Steril. 2006 Dec 1;86(6):1561–72.
- Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012 Sep 1;98(3):511-9.
- Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Diagnostic experience among 4,334
 women reporting surgically diagnosed endometriosis. Fertil Steril. 2009 Jan;91(1):32–9.
- 4. As-Sanie S, Soliman AM, Evans K, Erpelding N, Lanier RK, Katz NP. Short-acting and Long-acting
 Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A
 Population-based Claims Study. J Minim Invasive Gynecol. 2021 Feb 1;28(2):297-306.e2.
- Soliman AM, Surrey E, Bonafede M, Nelson JK, Castelli-Haley J. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States. Adv Ther.
 2018 Mar 1;35(3):408–23.
- 531 6. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical Treatment of Endometriosis: A 7532 Year Follow-up on the Requirement for Further Surgery. Obstet Gynecol. 2008
 533 Jun;111(6):1285.
- 534 7. Singh SS, Suen MWH. Surgery for endometriosis: beyond medical therapies. Fertil Steril. 2017
 535 Mar 1;107(3):549-54.

- **8**. Ellis K, Munro D, Clarke J. Endometriosis Is Undervalued: A Call to Action. Front Glob Womens
- 537 Health [Internet]. 2022 [cited 2022 Dec 1];3. Available from:
- 538 https://www.frontiersin.org/articles/10.3389/fgwh.2022.902371
- 539 9. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of
 540 endometriosis: costs and quality of life of women with endometriosis and treated in referral
 541 centres. Hum Reprod Oxf Engl. 2012 May;27(5):1292–9.
- 542 10. Penrod N, Okeh C, Velez Edwards DR, Barnhart K, Senapati S, Verma SS. Leveraging electronic
 543 health record data for endometriosis research. Front Digit Health [Internet]. 2023 Jun 5 [cited
 544 2024 Apr 12]; 5. Available from: https://www.frontiersin.org/journals/digital545 health/articles/10.3389/fdgth.2023.1150687/full
- 546 11. Soliman AM, Fuldeore M, Snabes MC. Factors Associated with Time to Endometriosis Diagnosis
 547 in the United States. J Womens Health. 2017 Jul;26(7):788–97.
- 548 12. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline:
 649 endometriosis†. Hum Reprod Open. 2022 Jan 1;2022(2):hoac009.
- 13. Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a
 systematic quantitative review. BJOG Int J Obstet Gynaecol. 2004 Nov;111(11):1204–12.
- 14. Nisolle M, Paindaveine B, Bourdon A, Berlière M, Casanas-Roux F, Donnez J. Histologic study of
 peritoneal endometriosis in infertile women. Fertil Steril. 1990 Jun;53(6):984–8.
- 15. Fauconnier A, Fritel X, Chapron C. [Endometriosis and pelvic pain: epidemiological evidence of
 the relationship and implications]. Gynecol Obstet Fertil. 2009 Jan;37(1):57–69.
- 16. Sapkota Y, Steinthorsdottir V, Morris AP, Fassbender A, Rahmioglu N, De Vivo I, et al. Metaanalysis identifies five novel loci associated with endometriosis highlighting key genes involved
 in hormone metabolism. Nat Commun. 2017 May 24;8(1):15539.
- 17. Rahmioglu N, Mortlock S, Ghiasi M, Møller PL, Stefansdottir L, Galarneau G, et al. The genetic
 basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat
 Genet. 2023 Mar;55(3):423–36.
- 562 18. Saha R, Pettersson HJ, Svedberg P, Olovsson M, Bergqvist A, Marions L, et al. Heritability of
 563 endometriosis. Fertil Steril. 2015 Oct 1;104(4):947–52.
- Lee SH, Harold D, Nyholt DR, Goddard ME, Zondervan KT, Williams J, et al. Estimation and
 partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple
 sclerosis and endometriosis. Hum Mol Genet. 2013 Feb 15;22(4):832–41.
- 567 20. Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes associated with
 568 chronic pelvic pain and endometriosis. Hum Reprod Update. 2014;20(5):737-47.
- 569 21. Nezhat C, Li A, Abed S, Balassiano E, Soliemannjad R, Nezhat A, et al. Strong Association
 570 Between Endometriosis and Symptomatic Leiomyomas. JSLS. 2016;20(3):e2016.00053.

- 571 22. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, et al. The Penn Medicine
 572 BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision
 573 Medicine in a Diverse Population. J Pers Med. 2022 Dec;12(12):1974.
- 574 23. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The Electronic
 575 Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med Off J
 576 Am Coll Med Genet. 2013 Oct;15(10):761–71.
- 577 24. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated
 578 genes and pathways across eMERGE Network | SpringerLink [Internet]. [cited 2023 Aug 14].
 579 Available from: https://link.springer.com/article/10.1186/s12916-019-1364-z
- 580 25. Data Browser | All of Us Public Data Browser [Internet]. [cited 2024 Mar 30]. Available from:
 581 https://databrowser.researchallofus.org/
- 582 26. Genomic data in the All of Us Research Program. Nature. 2024;627(8003):340-6.
- 583 27. The "All of Us" Research Program. N Engl J Med. 2019 Aug 15;381(7):668–76.
- 584 28. Sync For Science [Internet]. [cited 2024 Mar 30]. Available from: https://syncfor.science/
- 585 29. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
 586 with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.
- 30. Hallinan CM, Ward R, Hart GK, Sullivan C, Pratt N, Ng AP, et al. Seamless EMR data access:
 Integrated governance, digital health and the OMOP-CDM. BMJ Health Care Inform. 2024 Feb
 21;31(1):e100953.
- 590 31. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012 Nov 1;491(7422):56-65.
- Jia H, Ding S, Xu X, Nie R. The latest research progress on spectral clustering. Neural Comput
 Appl. 2014 Jun 1;24(7):1477-86.
- 33. Damle A, Minden V, Ying L. Simple, direct and efficient multi-way spectral clustering. Inf
 Inference J IMA. 2019 Mar 15;8(1):181–203.
- 34. Khan K, Rehman SU, Aziz K, Fong S, Sarasvady S. DBSCAN: Past, present and future. In: The Fifth
 International Conference on the Applications of Digital Information and Web Technologies
 (ICADIWT 2014) [Internet]. 2014 [cited 2024 Mar 30]. p. 232–8. Available from:
 https://ieeexplore.ieee.org/abstract/document/6814687
- 35. Algorithms for hierarchical clustering: an overview Murtagh 2012 WIREs Data Mining and
 Knowledge Discovery Wiley Online Library [Internet]. [cited 2024 Mar 30]. Available from:
 https://wires.onlinelibrary.wiley.com/doi/full/10.1002/widm.53
- 603 36. Kanungo T, Mount DM, Netanyahu NS, Piatko CD, Silverman R, Wu AY. An efficient k-means
 604 clustering algorithm: analysis and implementation. IEEE Trans Pattern Anal Mach Intell. 2002
 605 Jul;24(7):881–92.

- 606 37. Watts V. 9.5 Statistical Inference for Two Population Proportions. 2022 Sep 1 [cited 2024 Apr
- 607 16]; Available from: https://ecampusontario.pressbooks.pub/introstats/chapter/9-5608 statistical-inference-for-two-population-proportions/
- 38. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to
 the challenge of larger and richer datasets. GigaScience. 2015 Dec 1;4(1):s13742-015-0047–8.
- 39. Islam MJ, Wu QMJ, Ahmadi M, Sid-Ahmed MA. Investigating the Performance of Naive- Bayes
 Classifiers and K- Nearest Neighbor Classifiers. In: 2007 International Conference on
 Convergence Information Technology (ICCIT 2007) [Internet]. 2007 [cited 2024 Apr 16]. p.
 1541–6. Available from: https://ieeexplore.ieee.org/abstract/document/4420473
- 40. Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling
 for case-control imbalance and sample relatedness in large-scale genetic association studies.
 Nat Genet. 2018 Sep;50(9):1335–41.
- 41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set
 for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet. 2007
 Sep;81(3):559-75.
- 42. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and
 random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.
- 43. Heydarpour M, Parksook WW, Hopkins PN, Pojoga LH, Williams GH, Williams JS. A candidate
 locus in the renalase gene and susceptibility to blood pressure responses to the dietary salt. J
 Hypertens. 2023 May;41(5):723.
- 626 44. Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. Fine
 627 mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants
 628 with lymphoid gene enhancers. Nat Genet. 2015 Apr;47(4):381–6.
- 45. Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022 Dec;612(7941):720-4.
- 46. Stilley JAW, Segaloff DL. FSH Actions and Pregnancy: Looking Beyond Ovarian FSH Receptors.
 Endocrinology. 2018 Dec 1;159(12):4033-42.
- 47. Heidari S, Kolahdouz-Mohammadi R, Khodaverdi S, Tajik N, Delbandi AA. Expression levels of
 MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls.
 BMC Womens Health. 2021 Dec 20;21(1):422.
- 48. Amirteimouri S, Ashini M, Ramazanali F, Aflatoonian R, Afsharian P, Shahhoseini M. Epigenetic
 role of the nuclear factor NF-Y on ID gene family in endometrial tissues of women with
 endometriosis: a case control study. Reprod Biol Endocrinol. 2019 Mar 15;17(1):32.
- 49. Al-kuraishy HM, Al-Maiahy TJ, Al-Gareeb AI, Alexiou A, Papadakis M, Saad HM, et al. The
 possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review.
 Cancer Rep. 2024;7(1):e1920.

- 642 50. Kho PF, Wang X, Cuéllar-Partida G, Dörk T, Goode EL, Lambrechts D, et al. Multi-tissue
- 643 transcriptome-wide association study identifies eight candidate genes and tissue-specific gene
- 644 expression underlying endometrial cancer susceptibility. Commun Biol. 2021 Oct 21;4(1):1–8.